Solux Co. Ltd - Asset Resilience Ratio
Solux Co. Ltd (290690) has an Asset Resilience Ratio of 0.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Solux Co. Ltd (290690) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Solux Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Solux Co. Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Solux Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 290690 liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.00 Billion | 0.65% |
| Total Liquid Assets | ₩1.00 Billion | 0.65% |
Asset Resilience Insights
- Limited Liquidity: Solux Co. Ltd maintains only 0.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Solux Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Solux Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Solux Co. Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Solux Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.71% | ₩1.00 Billion ≈ $677.69K |
₩141.59 Billion ≈ $95.95 Million |
-13.40pp |
| 2023-12-31 | 14.11% | ₩22.60 Billion ≈ $15.32 Million |
₩160.17 Billion ≈ $108.54 Million |
-1.33pp |
| 2022-12-31 | 15.44% | ₩10.56 Billion ≈ $7.16 Million |
₩68.41 Billion ≈ $46.36 Million |
+11.64pp |
| 2021-12-31 | 3.80% | ₩2.81 Billion ≈ $1.90 Million |
₩73.88 Billion ≈ $50.07 Million |
-12.54pp |
| 2020-12-31 | 16.34% | ₩10.88 Billion ≈ $7.37 Million |
₩66.57 Billion ≈ $45.11 Million |
+4.71pp |
| 2019-12-31 | 11.63% | ₩5.61 Billion ≈ $3.80 Million |
₩48.23 Billion ≈ $32.68 Million |
-6.90pp |
| 2018-12-31 | 18.53% | ₩8.11 Billion ≈ $5.50 Million |
₩43.77 Billion ≈ $29.66 Million |
-- |
About Solux Co. Ltd
ARIBIO Holdings Inc. manufactures and supplies indoor, outdoor, and special purpose lighting products in South Korea and internationally. The company was formerly known as Solux Co., Ltd. and changed its name to ARIBIO Holdings Inc. in July 2026. ARIBIO Holdings Inc. was founded in 1995 and is headquartered in Gongju-si, South Korea.